Sonnet BioTherapeutics Reports a Safe and Tolerable Phase I Trial for SON-1010 in Healthy Volunteers

Sonnet BioTherapeutics Holdings, Inc., a clinical-stage company focusing on immunotherapeutic drugs for cancer, announced clinical data about SON-1010, demonstrating its safety and tolerability in healthy volunteers. Published in Frontiers in Immunology, the study shows SON-1010's potential in reducing tumor growth and enhancing immune response within the tumor microenvironment. This research highlights the importance of the SB102 study in healthy volunteers for setting the initial dose for further exploration in cancer patients.

SON-1010 combines interleukin 12 with Sonnet's proprietary FHAB technology, targeting tumor tissues and potentially improving immune-mediated cancer treatments. Despite observing more adverse effects at doses above 100 ng/kg, all effects were transient and aligned with expectations from interleukin-12 usage. The study suggests that SON-1010's targeted approach may enhance pharmacokinetics and pharmacodynamics, offering a non-toxic strategy against cancer.

Dr. Pankaj Mohan remarks on the findings as a significant milestone for Sonnet, underlying SON-1010's extended half-life and its potential synergy with checkpoint inhibitors to activate immune responses against cancer. The company aims to combine this innovation with other immunomodulators, expressing optimism about future applications in cell-based therapies.